DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for leukodystrophy, hypomyelinating, 16 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLeukodystrophy, hypomyelinating, 16 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for leukodystrophy, hypomyelinating, 16 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transmembrane protein 106B (TMEM106B) — TMEM106B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8OTD · 2.6 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 20-year-old man with 4H syndrome (ataxia, hypomyelination, hypodontia, hypogonadotropic hypogonadism) was found to have late-onset growth hormone deficiency without overt growth failure and carried two novel missense mutations, R1005H and A1331T, in POLR3A, the gene coding for the largest subunit of RNA polymerase III. This was the first report of this leukodystrophy from southeastern Europe. A 14-year-old girl with the same syndrome had severe cerebellar ataxia, tremor, dysmetria, could not walk or stand alone, had lost sphincter control, had immature expressive language, no pubertal development, and definitive hypodontia of upper central incisors; brain MRI showed diffuse hypomyelination confirmed by diffusion and spectroscopy studies. Only four patients with 4H syndrome had been reported before 2008.
A 2023 case report describes an infant with hypomyelinating leukodystrophy-13 (HLD-13) whose next-generation sequencing revealed a pathogenic homozygous variant. The authors note that most severe cases present in infancy and early childhood with significant neurological impairments, though some patients have mild presentations with symptom onset in adolescence or adulthood. Clinical features range from muscle stiffness to seizures and developmental delay. Diagnosis is typically made by MRI pattern recognition and next-generation sequencing.
A 2018 review states that leukodystrophies are typically considered incurable neurodegenerative disorders, often diagnosed after irreversible central and peripheral nervous system injury has occurred. The field is expanding rapidly due to advances in neuroimaging and genetics, but initial symptoms may mimic common paediatric disorders, causing diagnostic delay. A 2002 review notes that the term leukodystrophy was originally defined as progressive diseases of myelin with a molecular abnormality causing metabolic defects in myelin sheaths or myelin-forming cells, leading to confluent destruction or failed development of central white matter.
No clinical trial data, no tested therapies, and no survival or response rates are reported in any of these abstracts. What is missing is any prospective trial designed to test a treatment in POLR3A-related leukodystrophy, any systematic natural history study that could power such a trial, and any patient stratification by genotype or age at onset.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Neurology · 2012 · 58 citations
4H Syndrome With Late-Onset Growth Hormone Deficiency Caused by POLR3A Mutations
AbstractOBJECTIVE: To report a novel clinical and genetic presentation of a patient with 4H syndrome, which is a recently described leukodystrophy syndrome characterized by ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. DESIGN: Case report. SETTING: University teaching hospital. PATIENT: A 20-year-old male patient with 4H syndrome. RESULTS: The patient was found to have delayed tooth eruption and a late-onset growth hormone deficiency without overt growth failure. He was a compound heterozygote for the novel missense mutations R1005H and A1331T of POLR3A, which codes for the largest subunit of RNA polymerase III. CONCLUSION: This is the first report of this type of leukodystrophy from southeastern Europe, which suggests that POLR3A mutations should be suspected in patients with hypomyelination and various central nervous system–based endocrine abnormalities.
Hipomielinización central, hipogonadismo hipogonadotrófico e hipodontia: una nueva forma de leucodistrofia
AbstractAIM: To report one patient with slowly progressive encephalopathy, ataxia, central hypomyelination, hypodontia and hypogonadotropic hypogonadism, the 4H syndrome. This clinical picture has been described recently and there are only four patients reported previously. CASE REPORT: A girl with a previously normal early psychomotor development, presented a slowly progressive deterioration since 15 months of age. Now, she is 14 years old, and has a severe cerebellar ataxia, with tremor and dysmetria. She can't neither walk nor remain standing alone. She has lost the sphincter control and has an immature expressive language. She has no puberal development and definitive hypodontia of upper central incisors. The brain magnetic resonance imaging shows a diffuse hypomyelination, that is confirmed with diffusion and spectroscopy studies. CONCLUSION: The hypomyelinating leukoencephalopathies are disorders with abnormally low amount of myelin. The diagnosis is difficult in most of the patients. The hypomyelinating leukoencephalopathies include classic disorders and new leukoencephalopathies, described in the past few years.
CONTINUUM Lifelong Learning in Neurology · 2018 · 15 citations
Leukodystrophies
AbstractPURPOSE OF REVIEW: The leukodystrophies, typically considered incurable neurodegenerative disorders, are often diagnosed after irreversible central and peripheral nervous system injury has occurred. Early recognition of these disorders is imperative to enable potential therapeutic interventions. This article provides a summary of the symptoms of and diagnostic evaluation for leukodystrophies, along with the currently available therapies and recent advances in management. RECENT FINDINGS: The leukodystrophies are a rapidly expanding field because of advances in neuroimaging and genetics; however, recognition of the clinical and biochemical features of a leukodystrophy is essential to accurately interpret an abnormal MRI or genetic result. Moreover, the initial symptoms of leukodystrophies may mimic other common pediatric disorders, leading to a delay in the recognition of a degenerative disorder. SUMMARY: This article will aid the clinician in recognizing the clinical features of leukodystrophies and providing accurate diagnosis and management.
A Rare Case of Hypomyelinating Leukodystrophy and Its Management: A Case Report and Literature Review
AbstractA subset of hereditary white matter disorders called hypomyelinating leukodystrophies (HLD) is characterized primarily by the absence of myelin deposition. Although the clinical presentation can be mild and the development of symptoms can occur in adolescence or adulthood, the majority of severe cases present during infancy and early childhood with significant neurological impairments. The clinical features vary from muscle stiffness to seizures and developmental delay. The detailed myelination process can be seen with magnetic resonance imaging (MRI), and many patients are diagnosed using MRI pattern recognition and next-generation sequencing (NGS) in most cases. Here, we report a case of an infant suffering from the hypomyelinating leukodystrophy-13 (HLD-13) variant, whose next-generation sequencing revealed a pathogenic homozygous variant.
Cambridge University Press eBooks · 2002 · 0 citations
Leukodystrophies
AbstractThe term leukodystrophy was first introduced by Bielschowsky and Henneberg (1928). In his review of the neuropathology of the leukodystrophies, James Powers et al. (2000) recommended that the term leukodystrophy should be applied only to ‘those progressive diseases of myelin in which a molecular abnormality is responsible for metabolic defects in myelin sheaths or myelin forming cells resulting in confluent destruction, or failed development, of central white matter’. Since the 1990s, remarkable progress has been achieved in the definition of the biochemical defect and the molecular basis of the leukodystrophies (Table 100.1).
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
